Daily Ards Research Analysis
Three papers advance understanding and management of ARDS and related pulmonary conditions. A prospective cohort links early sFlt-1 to ARDS risk and mortality in sepsis, a small RCT compares immunomodulatory profiles of remimazolam vs dexmedetomidine in ARDS sedation, and a preclinical study identifies an interoceptive SFO–infralimbic cortex circuit by which airway inflammation impairs fear extinction with implications for ARDS survivors.
Summary
Three papers advance understanding and management of ARDS and related pulmonary conditions. A prospective cohort links early sFlt-1 to ARDS risk and mortality in sepsis, a small RCT compares immunomodulatory profiles of remimazolam vs dexmedetomidine in ARDS sedation, and a preclinical study identifies an interoceptive SFO–infralimbic cortex circuit by which airway inflammation impairs fear extinction with implications for ARDS survivors.
Research Themes
- Endothelial/VEGF pathway dysregulation as an ARDS driver
- Sedation strategy and immunomodulation in mechanically ventilated ARDS
- Lung–brain interoceptive circuits linking airway inflammation to behavior
Selected Articles
1. Soluble Fms-Like Tyrosine Kinase-1 Associates With Risk of Acute Respiratory Distress Syndrome and Mortality in Sepsis.
In 198 septic adults, higher early plasma sFlt-1 was associated with increased ARDS risk and mortality; causal mediation suggested ARDS accounts for about one-fifth of the sFlt-1–mortality association. Findings support dysregulated VEGF signaling in ARDS and identify sFlt-1 as a potential early endothelial target.
Impact: This study links an endothelial biomarker (sFlt-1) to both ARDS development and mortality in sepsis and quantifies ARDS-mediated risk, advancing mechanistic and prognostic understanding.
Clinical Implications: Early sFlt-1 measurement at ED admission could aid risk stratification for sepsis-associated ARDS and mortality and inform enrollment in endothelial-targeted trials; therapeutic modulation of VEGF/sFlt-1 pathways warrants testing.
Key Findings
- Among 198 septic patients, 29% developed ARDS within 6 days.
- Per-log increase in plasma sFlt-1 was associated with ARDS (OR 1.91; 95% CI 1.31–2.76; p<0.01).
- Per-log increase in sFlt-1 was associated with mortality (OR 2.19; 95% CI 1.57–3.08; p<0.01).
- ARDS mediated 20.3% (95% CI 6.9–98.1%) of the sFlt-1–mortality association.
Methodological Strengths
- Prospective cohort with early ED plasma sampling.
- Adjusted logistic regression and causal mediation analysis to quantify indirect effects.
Limitations
- Single-center cohort with modest sample size may limit generalizability.
- Observational design; residual confounding and causality cannot be excluded.
- Use of Sepsis-2 criteria may affect comparability with Sepsis-3–based cohorts.
Future Directions: Validate sFlt-1 thresholds in multicenter cohorts and test endothelial-targeted interventions (e.g., modulating VEGF/sFlt-1) in randomized trials for sepsis-associated ARDS.
IMPORTANCE: The vascular endothelial growth factor (VEGF) signaling pathway is important in the pathogenesis of acute respiratory distress syndrome (ARDS) with supportive genetic and proteomic evidence. Genetic polymorphisms within FLT1, which encodes VEGF receptor 1, associate with risk of ARDS in sepsis. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is a secreted splice variant of FLT1 that acts as a potent antagonist to circulating VEGF. OBJECTIVES: To assess the association between early plasma concentrations of sFlt-1 and risk of ARDS and to determine if ARDS mediates the relationship between sFlt-1 and mortality during sepsis. DESIGN, SETTING, AND PARTICIPANTS: In a prospective cohort study, we enrolled 198 critically ill patients with sepsis per Sepsis-2 criteria. ARDS was defined per Berlin criteria. MAIN OUTCOMES AND MEASURES: Levels of sFlt-1 were quantified using electrochemiluminescence on plasma collected in the emergency department upon admission. We tested the association between plasma levels of sFlt-1 with ARDS and mortality using logistic regression adjusting for age, sex, and pulmonary versus nonpulmonary source of sepsis. We applied causal mediation analysis to determine the percentage of the total effect of sFlt-1 on mortality that was mediated by ARDS. RESULTS: We enrolled 198 patients; ARDS developed within 6 days in 29%. Plasma levels of sFlt-1 were significantly associated with risk of ARDS in sepsis (odds ratio [OR], 1.91 per log increase; 95% CI, 1.31-2.76 per log increase; p < 0.01). Plasma sFlt-1 levels were also associated with mortality (OR, 2.19 per log increase; 95% CI, 1.57-3.08 per log increase; p < 0.01). ARDS mediated 20.3% (95% CI, 6.9-98.1%) of the total effect of sFlt-1 on mortality (p < 0.01). CONCLUSIONS AND RELEVANCE: Higher plasma levels of sFlt-1 were associated with an increased risk of ARDS and ARDS mediated a significant proportion of the sFlt-1-associated mortality observed during sepsis. Our findings further implicate dysregulated VEGF signaling in ARDS and suggest that plasma sFlt-1 merits further investigation as an early endothelial therapeutic target for sepsis-associated ARDS and mortality.
2. A novel interoceptive subfornical organ to infralimbic cortex circuit relays airway inflammation effects on fear extinction.
In a murine allergic airway inflammation model, severe (but not mild) inflammation impaired fear extinction via an IL-17–dependent mechanism involving SFO microglial IL-17RA and a direct SFO-to-infralimbic cortex circuit; targeting IL-17 or this interoceptive pathway restored extinction. The work reveals a body-to-brain route by which pulmonary inflammation could drive neuropsychiatric sequelae relevant to ARDS survivors.
Impact: This preclinical study identifies a novel interoceptive SFO–infralimbic circuit and IL-17–microglia signaling linking airway inflammation to cortical dysfunction, a mechanistic advance with translational implications for pulmonary diseases including ARDS.
Clinical Implications: Suggests need to monitor and address neuropsychiatric outcomes (e.g., PTSD-like phenotypes) after severe pulmonary inflammation; IL-17 signaling or SFO–prefrontal circuits might be therapeutic targets pending human validation.
Key Findings
- Severe, but not mild, airway inflammation impaired fear extinction; anti–IL-17A antibodies abolished this effect.
- IL-17RA was expressed and upregulated in SFO microglia in severe inflammation; microglial IL-17RA ablation improved extinction.
- Direct SFO projections to infralimbic cortex were identified; chemogenetic inhibition of the SFO–IL circuit restored extinction.
Methodological Strengths
- Multi-level mechanistic approach combining behavior, immunology, microglia-specific receptor manipulation, anatomical tracing, and chemogenetics.
- Severity-stratified airway inflammation model enabling causal inference about IL-17 signaling.
Limitations
- Preclinical murine model; generalizability to humans is uncertain.
- Preprint (not peer-reviewed) at the time of analysis.
- Airway inflammation modeled as allergic asthma; extrapolation to ARDS is indirect.
Future Directions: Translate to humans via neuroimaging and cytokine profiling in ARDS and pneumonia cohorts; test IL-17–targeted or circuit-based neuromodulation to prevent post–pulmonary inflammation fear pathology.
There is growing interest in the impact of internal body states on the brain and behavior. The detrimental effects of chronic lung inflammation on mental health are well recognized, however, underlying mechanisms are not known. Here, using a murine model of allergic asthma we report compromised fear extinction in mice with severe but not mild airway inflammation (AI); an effect abolished by anti-interleukin-17A (IL-17A) antibodies. Investigation of innate immune cells, microglia as-well-as transcriptomic signatures in the subfornical organ (SFO), a brain interoceptive node lacking a traditional blood-brain-barrier, revealed significant alterations in severe AI mice. IL-17 Receptor A (IL-17RA) was expressed in SFO microglia and upregulated in severe AI mice. Notably, ablation of microglial IL-17RA improved fear extinction in severe AI mice. Furthermore, we identified direct SFO projections to the infralimbic (IL) cortex, a key area regulating extinction. Importantly, chemogenetic inhibition of the SFO-IL circuit led to improved fear extinction in severe AI mice. Collectively, we report a unique body-to-brain interoceptive mechanism engaging the SFO and an SFO-to-IL circuit, through which airway inflammatory mediators compromise fear extinction. Beyond asthma, our findings are relevant to other pulmonary pathologies (e.g. bacterial pneumonia, ARDS, COVID-19) highlighting a risk for cortical dysfunction and fear pathologies such as PTSD.
3. Comparison of remimazolam besylate and dexmedetomidine on stress response and immune balance in patients with acute respiratory distress syndrome.
In a single-center RCT of 60 ventilated ARDS patients, remimazolam and dexmedetomidine achieved comparable sedation depth without serious adverse events, but differed in stress and cytokine responses: lower cortisol with remimazolam at 48 h and distinct IL profiles (e.g., lower IL-6 with dexmedetomidine). Results support individualized, immunomodulation-aware sedation strategies.
Impact: This pilot RCT directly compares two commonly used sedatives in ARDS and uncovers divergent immunoendocrine effects beyond sedation depth, informing precision sedation research.
Clinical Implications: Choice of sedative in ARDS may be tailored to immunoendocrine goals (e.g., HPA-axis suppression with remimazolam vs cytokine modulation with dexmedetomidine); larger trials should test whether these profiles translate into outcome differences.
Key Findings
- Sixty ARDS patients requiring ≥72 h of mechanical ventilation were randomized to remimazolam or dexmedetomidine with standardized analgesia.
- At 48 h, cortisol was significantly lower with remimazolam (P=0.013).
- Inflammatory cytokine profiles diverged: IL-4 and IL-10 lower with remimazolam; IL-6 lower with dexmedetomidine; IL-4 and IL-17 increased over 48 h with dexmedetomidine.
- Sedation depth (RASS) was similar between groups and no serious adverse events occurred.
Methodological Strengths
- Randomized, prospective design with standardized sedation assessment (RASS).
- Serial measurement of stress hormones and cytokines enabling dynamic comparison.
Limitations
- Single-center, small sample size; underpowered for clinical outcomes.
- Primary endpoints were biomarkers; no long-term or patient-centered outcomes reported.
Future Directions: Conduct multicenter RCTs powered for clinical endpoints (ventilator-free days, mortality) and explore phenotype-guided sedation based on immunoendocrine profiles.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by disruption of the alveolar-capillary barrier, non-cardiogenic pulmonary edema, and severe hypoxemia. Its core pathophysiology involves uncontrolled systemic inflammation and oxidative stress injury. Mechanical ventilation remains the primary respiratory support strategy for ARDS, but may aggravate lung injury and trigger stress responses. Therefore, developing individualized sedation strategies to regulate stress and inflammatory responses is critical to improving patient outcomes. This study aimed to compare the sedative effects of remimazolam besylate and dexmedetomidine in mechanically ventilated ARDS patients, and to evaluate their dynamic impact on stress markers and inflammatory cytokines, in order to explore their differences in immunomodulation. METHODS: This single-center, prospective, randomized controlled trial enrolled ICU patients who met the diagnostic criteria for ARDS and required mechanical ventilation for ≥ 72 h. A total of 60 patients were randomly assigned to receive either dexmedetomidine or remimazolam besylate, with both groups receiving standard analgesia and continuous infusion of the assigned sedative. Sedation depth was assessed using the Richmond Agitation-Sedation Scale (RASS), and stress markers and inflammatory cytokines were measured for comparative analysis. RESULTS: Baseline characteristics were comparable between the two groups. At 48 h post-administration, the cortisol level in the remimazolam group was significantly lower than in the dexmedetomidine group (P = 0.013). Regarding inflammatory cytokines, IL-4 and IL-10 levels were lower in the remimazolam group, while IL-6 was lower in the dexmedetomidine group. Additionally, IL-4 and IL-17 levels significantly increased in the dexmedetomidine group after 48 h (P < 0.05), suggesting its potential role in promoting Th2 immune responses and anti-inflammatory pathways. There was no significant difference in sedation depth between the two groups, and no serious adverse events were reported. CONCLUSION: Both remimazolam besylate and dexmedetomidine provide effective sedation in patients with ARDS; however, they differ significantly in their effects on stress modulation and inflammatory regulation. Remimazolam besylate may reduce stress responses primarily by suppressing activation of the hypothalamic-pituitary-adrenal (HPA) axis, while dexmedetomidine may exert its effects through modulation of Th2 immune responses and inflammatory cytokine release. These findings offer new evidence to support individualized sedation strategies in the management of ARDS.